Identification

Name
Plerixafor
Accession Number
DB06809
Type
Small Molecule
Groups
Approved
Description

Plerixafor is a hematopoietic stem cell mobilizer. It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin lymphoma and multiple myeloma for the purpose of stimulating the immune system. These stem cells are then collected and used in autologous stem cell transplantation to replace blood-forming cells that were destroyed by chemotherapy. Plerixafor has orphan drug status in the United States and European Union; it was approved by the U.S. Food and Drug Administration on December 15, 2008.

Structure
Thumb
Synonyms
Not Available
External IDs
AMD-3100 / AMD3100
Product Ingredients
IngredientUNIICASInChI Key
Plerixafor octahydrochlorideOD49913540155148-31-5UEUPDYPUTTUXLJ-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MozobilSolution24 mg/1.2mLSubcutaneousGenzyme Corporation2008-12-15Not applicableUs
MozobilSolution24 mg/1.2mLSubcutaneousSanofi Aventis2013-09-01Not applicableUs
MozobilSolution20 mgSubcutaneousSanofi Aventis2012-03-26Not applicableCanada
Categories
UNII
S915P5499N
CAS number
110078-46-1
Weight
Average: 502.782
Monoisotopic: 502.447143768
Chemical Formula
C28H54N8
InChI Key
YIQPUIGJQJDJOS-UHFFFAOYSA-N
InChI
InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2
IUPAC Name
1-{[4-(1,4,8,11-tetraazacyclotetradecan-1-ylmethyl)phenyl]methyl}-1,4,8,11-tetraazacyclotetradecane
SMILES
C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1

Pharmacology

Indication

Used in combination with granulocyte-colony stimulating factor (G-CSF, filgrastim) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).

Structured Indications
Not Available
Pharmacodynamics

Plerixafor is a bicyclam derivative that antagonizes CXCR4 by binding to three acidic residues in the ligand-binding pocket: Asp171, Asp262, and Glu288. Blood levels of CD34+ cells peaked at 9 hours after administration of 0.24 mg/kg plerixafor in healthy subjects. In patients that have non-Hodgkin’s lymphoma or multiple myeloma, blood levels of CD34+ peaked at 6 hours. In combination with a G-CSF, circulating CD34+ cells in the peripheral blood peaked at 9-14 hours.

Mechanism of action

Plerixafor inhibits the CXCR4 chemokine receptors on CD34+ cells and reversibly blocks binding of the ligand, stromal cell-derived factor-1-alpha (SDF-1α). By blocking the interaction between SDF-1α and CXCR4 with plerixafor, mobilization of progenitor cells is triggered. Filgrastim, a granulocyte-colony stimulating factor, is added to enhance CD34+ cell mobilization, thus increasing the yield of stem cells- an important determinant of graft adequacy.

TargetActionsOrganism
AC-X-C chemokine receptor type 4
antagonist
Human
Absorption

Pharmacokinetic profile follows a two-compartment model with first-order absorption. A median peak plasma concentration of 0.24 mg/kg of plerixafor occurred 30-60 minutes after subcutaneous dose.

Volume of distribution

0.3 L/kg

Protein binding

58%

Metabolism

Metabolism does not involved CYP isoenzymes

Route of elimination

0.24 mg/kg, healthy subjects: ~70% of the parent drug is excreted in urine in the first 24 hours.

Half life

Terminal elimination half-life, NHL patients: 4.4 hours; Terminal elimination half-life, MM patients: 5.6 hours; Terminal elimination half-life, Hodgkin's lymphoma patients: 3.5 hours; Distribution half-life: 0.3 hours

Clearance

Total plasma clearance: 4.38 L/h; Renal clearance: 3.15 L/h

Toxicity

LD50, mouse, SC: 16.3 mg/kg; LD50, rat, SC: >50 mg/kg; LD50, mouse and rat, IV injection: 5.2 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
No interactions found.
Food Interactions
Not Available

References

General References
  1. Uy GL, Rettig MP, Cashen AF: Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther. 2008 Nov;8(11):1797-804. doi: 10.1517/14712598.8.11.1797 . [PubMed:18847313]
  2. Fricker SP: A novel CXCR4 antagonist for hematopoietic stem cell mobilization. Expert Opin Investig Drugs. 2008 Nov;17(11):1749-60. doi: 10.1517/13543784.17.11.1749 . [PubMed:18922110]
  3. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M, Cooper D, Bridger G, Calandra G: Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009 Jun 4;113(23):5720-6. doi: 10.1182/blood-2008-08-174946. Epub 2009 Apr 10. [PubMed:19363221]
  4. Stewart DA, Smith C, MacFarland R, Calandra G: Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant. 2009 Jan;15(1):39-46. doi: 10.1016/j.bbmt.2008.10.018. [PubMed:19135941]
  5. Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee SL, Saber H, Fourie J, Tornoe C, Booth B, Yuan W, He K, Justice R, Pazdur R: FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology. 2010;78(3-4):282-8. doi: 10.1159/000315736. Epub 2010 Jun 8. [PubMed:20530974]
  6. Choi HY, Yong CS, Yoo BK: Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma. Ann Pharmacother. 2010 Jan;44(1):117-26. doi: 10.1345/aph.1M380. Epub 2009 Dec 15. [PubMed:20009003]
  7. Keating GM: Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs. 2011 Aug 20;71(12):1623-47. doi: 10.2165/11206040-000000000-00000. [PubMed:21861545]
External Links
Human Metabolome Database
HMDB15681
KEGG Drug
D08971
PubChem Compound
65015
PubChem Substance
99443297
ChemSpider
58531
BindingDB
50035696
ChEBI
125354
ChEMBL
CHEMBL18442
PharmGKB
PA165958410
IUPHAR
844
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Plerixafor
ATC Codes
L03AX16 — Plerixafor
AHFS Codes
  • 20:16.00 — Hematopoietic Agents
FDA label
Download (270 KB)
MSDS
Download (86.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / All / Leukemia Acute Myeloid Leukemia (AML) / Relapsed/Refractory ALL / Relapsed/Refractory AML / Secondary AML/MDS1
1Active Not RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myeloid Leukemia (CML) / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Leukemias1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentImpaired Renal Function1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1CompletedTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
1CompletedTreatmentMobilization of hematopoietic stem cells therapy1
1CompletedTreatmentMyelodysplastic Syndromes1
1CompletedTreatmentNeutropenias1
1CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentStem Cell Transplant Patients1
1CompletedTreatmentTransplantation, Stem Cell1
1RecruitingSupportive CareSickle Cell Disorders1
1RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD) / Cystic Fibrosis (CF) / Pulmonary Fibrosis1
1RecruitingTreatmentCongenital Hypoplastic Anemia1
1RecruitingTreatmentHLA-A*0201 Positive Cells Present / Locally Advanced Malignant Neoplasm / NY-ESO-1 Positive / Unresectable Malignant Neoplasm1
1RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus 1 Positive / Stage I Adult Hodgkin Lymphoma / Stage I Adult Non-Hodgkin Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Adult Non-Hodgkin Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Non-Hodgkin Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Non-Hodgkin Lymphoma1
1RecruitingTreatmentHypogammaglobulinemia / Myelokathexis / Neutrophil Disorder / WHIMS1
1RecruitingTreatmentMalignant Neoplasm of Pancreas1
1RecruitingTreatmentMetastatic Colorectal Cancers / Ovarian Serous Adenocarcinoma / Pancreatic Adenocarcinoma Metastatic1
1RecruitingTreatmentPlasma Cell Myeloma1
1RecruitingTreatmentSickle Cell Disease Without Crisis1
1RecruitingTreatmentSickle Cell Disorders2
1TerminatedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligodendroglioma (AO) / High Grade Glioma: Glioblastoma (GBM) / High Grade Glioma: Gliosarcoma / Mixed Anaplastic Oligoastrocytoma (AOA)1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Malignant Lymphomas / Multiple Myeloma (MM)1
1TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1TerminatedTreatmentPediatric Acute Lymphoblastic Leukemia, Relapsed / Pediatric Acute Myeloblastic Leukemia, Relapsed1
1Unknown StatusTreatmentEnd Stage Liver Diseases1
1WithdrawnTreatmentDiabetic Ulcers1
1, 2Active Not RecruitingTreatmentAdult Ependymoblastoma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Medulloblastoma / Adult Mixed Glioma / Adult Oligodendroglial Tumors / Adult Pineoblastoma / Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)1
1, 2Active Not RecruitingTreatmentAdult Glioblastoma / Adult Gliosarcoma / Glioblastomas / Gliosarcoma1
1, 2Active Not RecruitingTreatmentFailure of Bone Marrow Graft1
1, 2Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2Active Not RecruitingTreatmentRecurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma1
1, 2CompletedSupportive CareCongenital Hypoplastic Anemia1
1, 2CompletedTreatmentAcute Myeloblastic Leukemia1
1, 2CompletedTreatmentEwing's Sarcoma/Soft Tissue Sarcoma / Neoplasms, Brain / Neuroblastomas1
1, 2CompletedTreatmentHigh Risk Myelodysplastic Syndrome / Leukemia Acute Myeloid Leukemia (AML)1
1, 2CompletedTreatmentHodgkins Disease (HD) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphoblastic, Acute / Leukemia, Myelogenous, Chronic / Lymphocytic Leukemia, Chronic / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2CompletedTreatmentLeukemias / Transplantation, Stem Cell1
1, 2CompletedTreatmentMultiple Myeloma (MM)1
1, 2RecruitingTreatmentCongenital Hypoplastic Anemia2
1, 2RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentMajor Sickle Cell Syndrome of Type SS or Sβ Thalassemia1
1, 2RecruitingTreatmentTransplants and Implants1
1, 2TerminatedTreatmentAcute Myelogenous Leukaemia (AML)1
1, 2WithdrawnTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2CompletedSupportive CareMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / For Donors / For Recipients / Hodgkins Disease (HD) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL) / Related Donors Donating PBSC to a Family Member1
2CompletedTreatmentAutologous Stem Cell Transplantation1
2CompletedTreatmentAutologous Stem Cell Transplantation / Lymphoma, Hodgkins / Mobilization of hematopoietic stem cells therapy / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentBlood And Marrow Transplantation1
2CompletedTreatmentBlood Component Removal / Healthy Volunteers1
2CompletedTreatmentBlood Stem Cell Harvest Failure1
2CompletedTreatmentChildren Cancer, Solid Tumor1
2CompletedTreatmentHodgkins Disease (HD)1
2CompletedTreatmentHodgkins Disease (HD) / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphocytic, Chronic, B-Cell / Multiple Myeloma (MM) / Myelodysplastic Syndromes / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentHodgkins Disease (HD) / Malignant Lymphomas / Multiple Myeloma (MM) / Non Hodgkin Lymphoma (NHL)1
2CompletedTreatmentHodgkins Disease (HD) / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentMalignant Lymphoma, Stem Cell Type1
2CompletedTreatmentMalignant Lymphomas1
2CompletedTreatmentMalignant Lymphomas / Multiple Myeloma (MM)1
2CompletedTreatmentMalignant Lymphomas / Plasma Cell Myeloma1
2CompletedTreatmentMultiple Myeloma (MM)2
2CompletedTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)5
2CompletedTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2CompletedTreatmentNeoplasms, Hematologic1
2CompletedTreatmentPlasma Cell Myeloma1
2CompletedTreatmentTransplantation, Autologous1
2RecruitingBasic ScienceChronic Granulomatous Disease X-linked (X-CGD)1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentCongenital Hypoplastic Anemia1
2RecruitingTreatmentCritical Limb Ischemia (CLI) / Diabetes Mellitus (DM) / Wounds1
2RecruitingTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma / Stem Cell Transplant Complications1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Refractory Diffuse Large B-cell Lymphoma (DLBCL) / Relapsed Diffuse Large B-cell Lymphoma (DLBCL)1
2RecruitingTreatmentMultiple Myeloma (MM)1
2RecruitingTreatmentScleroderma, Systemic1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelocytic Leukemia / Chronic Myelocytic Leukemia / Granulocytic Sarcoma / Hodgkin's or Non-Hodgkin's Lymphoma / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / For Donors / For Recipients / Hodgkins Disease (HD) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL) / Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling1
2TerminatedTreatmentMultiple Myeloma (MM)1
2TerminatedTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentSevere Combined Immunodeficiency1
2TerminatedTreatmentT-Cell Non-Hodgkin Lymphoma1
2WithdrawnTreatmentHematopoietic Stem Cells / Malignant Lymphomas / Multiple Myeloma (MM) / Transplantation, Bone Marrow1
3CompletedTreatmentFront Line Mobilization / Hodgkin's Disease or Multiple Myeloma / Lymphoma (Non-Hodgkin's Lymphoma) / Transplantations1
3CompletedTreatmentMultiple Myeloma (MM)1
3CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
3RecruitingTreatmentMyelokathexis / Neutropenias / Warts / WHIMS1
3TerminatedTreatmentRefractory Multiple Myeloma1
4CompletedNot AvailableBone Marrow / Autologous Transplants1
4CompletedTreatmentDiabetes Mellitus (DM)1
4CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
4Not Yet RecruitingTreatmentAutologous Stem Cell Transplantation1
Not AvailableApproved for MarketingNot AvailableAutologous Stem Cell Transplant1
Not AvailableCompletedNot AvailableLeukemia Acute Myeloid Leukemia (AML)1
Not AvailableCompletedNot AvailableMalignant Lymphomas / Plasma Cell Myeloma1
Not AvailableCompletedNot AvailableMultiple Myeloma (MM) / Transplantation, Autologous1
Not AvailableCompletedNot AvailableNon-Hodgkin's Lymphoma (NHL) / Transplantation, Autologous1
Not AvailableCompletedTreatmentBeta-Thalassemia1
Not AvailableNo Longer AvailableNot AvailableHodgkins Disease (HD) / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableTerminatedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Atypical Chronic Myeloid Leukemia, BCR-ABL Negative / Blastic Phase Chronic Myelogenous Leukemia / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma1
Not AvailableTerminatedTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableUnknown StatusTreatmentLymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma (MM) / Plasma Cell Dyscrasia1
Not AvailableUnknown StatusTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionSubcutaneous20 mg
SolutionSubcutaneous24 mg/1.2mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6987102No2006-01-172023-07-22Us
US7897590No2011-03-012023-03-22Us
USRE42152No1998-12-102018-12-10Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)131.5 °CFDA label
water solubilitySolubleMSDS
pKa6.0 - 7.5MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.0472 mg/mLALOGPS
logP0.62ALOGPS
logP-0.43ChemAxon
logS-4ALOGPS
pKa (Strongest Basic)10.54ChemAxon
Physiological Charge4ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area78.66 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity155.01 m3·mol-1ChemAxon
Polarizability60.51 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.932
Blood Brain Barrier+0.6867
Caco-2 permeable-0.5403
P-glycoprotein substrateSubstrate0.8076
P-glycoprotein inhibitor INon-inhibitor0.8119
P-glycoprotein inhibitor IINon-inhibitor0.7683
Renal organic cation transporterInhibitor0.5069
CYP450 2C9 substrateNon-substrate0.8905
CYP450 2D6 substrateSubstrate0.5274
CYP450 3A4 substrateNon-substrate0.7818
CYP450 1A2 substrateNon-inhibitor0.8787
CYP450 2C9 inhibitorNon-inhibitor0.9272
CYP450 2D6 inhibitorNon-inhibitor0.7149
CYP450 2C19 inhibitorNon-inhibitor0.9114
CYP450 3A4 inhibitorNon-inhibitor0.8817
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.926
Ames testNon AMES toxic0.7906
CarcinogenicityNon-carcinogens0.9106
BiodegradationNot ready biodegradable0.9824
Rat acute toxicity2.1178 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5
hERG inhibition (predictor II)Inhibitor0.6334
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylmethylamines
Direct Parent
Phenylmethylamines
Alternative Parents
Benzylamines / Aralkylamines / Trialkylamines / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenylmethylamine / Benzylamine / Aralkylamine / Tertiary aliphatic amine / Tertiary amine / Azacycle / Organoheterocyclic compound / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation. Acts as a receptor for extracellular ubiq...
Gene Name
CXCR4
Uniprot ID
P61073
Uniprot Name
C-X-C chemokine receptor type 4
Molecular Weight
39745.055 Da
References
  1. Uy GL, Rettig MP, Cashen AF: Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther. 2008 Nov;8(11):1797-804. doi: 10.1517/14712598.8.11.1797 . [PubMed:18847313]
  2. Jujo K, Ii M, Sekiguchi H, Klyachko E, Misener S, Tanaka T, Tongers J, Roncalli J, Renault MA, Thorne T, Ito A, Clarke T, Kamide C, Tsurumi Y, Hagiwara N, Qin G, Asahi M, Losordo DW: CXC-chemokine receptor 4 antagonist AMD3100 promotes cardiac functional recovery after ischemia/reperfusion injury via endothelial nitric oxide synthase-dependent mechanism. Circulation. 2013 Jan 1;127(1):63-73. doi: 10.1161/CIRCULATIONAHA.112.099242. Epub 2012 Nov 30. [PubMed:23204107]

Drug created on September 14, 2010 10:21 / Updated on December 10, 2017 17:18